Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MCT1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MCT1 Extracellular Loop / CD147 Complex Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View MCT1 Products |
| Gene Delivery | MCT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for 12-TM conformational preservation. |
View MCT1 Products |
| Benchmark Ab | Anti-MCT1 Recombinant Antibody Recombinant positive control derived from clinical-grade sequences. |
View MCT1 Products |
| Validator | MCT1 siRNA Set For knockdown verification in target-specificity assays. |
View MCT1 Products |
| Related Target A | MCT4 (SLC16A3) Key counter-screening target. MCT4 upregulation is a primary resistance mechanism bypass to MCT1 inhibitors. |
View MCT4 Products |
| Related Target B | CD147 (BSG) Essential chaperone protein required for the stable membrane translocation and functional activity of MCT1. |
View CD147 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 12-TM Membrane Conformation Preservation | High-titer Lentivirus Premade Particles for stable cell line construction, eliminating the need for unstable cell-free systems |
| MCT4 Selectivity Counter-Screening | Sequence-verified MCT4 lentiviruses and recombinant proteins available for parallel specificity assays |
| Lack of Clinical Reference Controls | Clinical benchmark recombinant antibodies synthesized with precise sequence validation |
| Assay Off-Target Noise | Highly purified CD147/Basigin chaperone proteins to validate MCT1-CD147 complex disruption |
Live MCT1/SLC16A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Monocarboxylate Transporter 1 (MCT1/SLC16A1) is a rapidly evolving frontier in cancer metabolism. MCT1 acts as a primary gatekeeper for lactate transport, facilitating both the efflux of lactate in glycolytic "warburg-effect" tumor cells and the influx of lactate in oxidative tumor cells. By disrupting this metabolic symbiosis, MCT1 inhibitors induce intracellular acidosis and metabolic starvation in cancer cells.
The race for MCT1 therapeutics is intensifying, with major players shifting focus from traditional small molecule inhibitors (SMIs) to combination regimens with immunotherapies and the exploration of antibody-drug conjugates (ADCs) targeting the MCT1/CD147 complex. As first-generation therapies like AZD3965 reach clinical milestones, the next wave of R&D is targeting dual MCT1/MCT4 inhibition to prevent the rapid development of drug resistance mediated by transporter redundancy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | AstraZeneca, Cancer Research UK | Diffuse Large B-Cell Lymphoma (DLBCL), Solid Tumors | Functional Lactate Transport Assay (Requires stable overexpressing cell lines via Lentivirus) |
| Monoclonal Antibodies / ADCs | Academic & Biopharma Consortia | Glycolytic Solid Tumors, Triple-Negative Breast Cancer | Cell-surface binding & internalization assays (Requires CD147 co-expression models) |
| Dual MCT1/MCT4 Inhibitors | Preclinical Biotech Developers | Advanced Refractory Cancers | Selectivity profiling (Requires parallel MCT1 and MCT4 overexpressing cell lines) |